Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.

PloS one - 1 Jan 2000

Yang Jingyu, Niu Heng, Huang Yingze, Yang Kunxian

Abstract excerpt

BACKGROUND: CDH13 (cadherin 13) is a special cadherin cell adhesion molecule, and the methylation of its promoter causes inactivation in a considerable number of human cancers. To explore the association between CDH13 promoter methylation and breast cancer risk and prognosis, we systematically integrated published articles to investigate the diagnostic performance of the CDH13 methylation test for breast cancer....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cadherins
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to CDH13 gene

Share to Genetic Predisposition to Disease

Share to Prognosis

Share to Promoter Regions, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 27153114
DOI: 10.1371/journal.pone.0149185
PMCID: PMC4859545

Genes

CDH13

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.PMID 27153114Read ↗

CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patientsSemantic proximity Read ↗

Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non Muscle Invasive Bladder CancerSemantic proximity Read ↗

Clinical and prognostic effects ofCDKN2A,CDKN2BandCDH13promoter methylation in ovarian cancer: a study using meta-analysis and TCGA dataSemantic proximity Read ↗

[Effect of genetics, epigenetics and variations in the transcriptional expression of cadherin-E in breast cancer susceptibility].Semantic proximity Read ↗

Clinical Significance of CDH13 Promoter Methylation in Serum Samples from Patients with Bladder Transitional Cell CarcinomaSemantic proximity Read ↗

Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancerSemantic proximity Read ↗

E‐cadherin deregulation in breast cancerSemantic proximity Read ↗

Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factorsSemantic proximity Read ↗

Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer PatientsSemantic proximity Read ↗

CDH1/E-cadherin and solid tumors. An updated gene-disease association analysis using bioinformatics tools.Semantic proximity Read ↗

ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.Semantic proximity Read ↗

Correlations of EZH2 and SMYD3 gene polymorphisms with breast cancer susceptibility and prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.